CTT Pharma gains U.S. patent for delivery tech
CTT Pharmaceutical Holdings, Inc. reports that the U.S. Patent and Trademark Office has approved a continuation-in-part patent for its micelle-based delivery technology, effective August 11, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
CTT Pharmaceutical Holdings, Inc. reports that the U.S. Patent and Trademark Office has approved a continuation-in-part patent for its micelle-based delivery technology, effective August 11, 2026. The patent adds protection for formulations delivering nicotine, vitamins, and caffeine and supports multiple dosage forms, including dissolvable strips, gum, pouches, lozenges, and dissolving tablets. The company describes this as part of its strategy to strengthen its patent portfolio around oral drug delivery systems designed for rapid onset, patient convenience, and efficient absorption across pharmaceutical, therapeutic, and nutraceutical markets.
Positive
- New U.S. continuation-in-part patent approved for micelle delivery technology covering nicotine, vitamins, and caffeine across multiple oral dosage forms, expanding CTT’s intellectual property protection.
- The patent supports dissolvable strips, gum, pouches, lozenges, and dissolving tablets, potentially broadening application of CTT’s oral drug delivery platform.
Negative
- None.
8-K Event Classification
Key Figures
Key Terms
continuation-in-part (CIP) regulatory
micelle delivery technology technical
oral drug delivery systems medical
thin film platform technical
nutraceutical markets medical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did CTT Pharmaceutical Holdings (CTTH) announce in this 8-K?
What does the new CIP patent for CTTH specifically cover?
When does CTTH’s new U.S. patent become effective?
What is a continuation-in-part (CIP) patent as used by CTTH?
What business focus does CTT Pharmaceutical Holdings (CTTH) highlight?
How does CTTH view the importance of patents to its strategy?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of Principal Executive Offices) (Zip Code) |
| (Registrant’s Telephone Number, Including Area Code) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Securities registered pursuant to Section 12(b) of the Act: | ||
| Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) received a continuation-in-part (CIP) approval from The United States Patent Office for the company’s micelle delivery technology. The patent was issued a patent number and became effective August 11, 2026. This patent specifically covers nicotine, vitamins, and caffeine and allows our technology to be used for dissolvable strips, gum, pouches, lozenges, and dissolving tablets.
Item 9.01 Financial Statements and Exhibits
(b) Exhibits
| Exhibit | Description | |
| 99.1 | Press Release | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CTT PHARMACEUTICAL HOLDINGS, INC. | ||||
| (Registrant) | ||||
| Date: 8/12/2026 | By: | /s/ Ryan Khouri | ||
| Name: | Ryan Khouri | |||
| Title: | ||||
Exhibit 99.1
CTT Pharma Receives U.S. Patent Approval for Nicotine, Vitamins, and Caffeine Delivery Technology
NEWSWIRE – August 10, 2026 - CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) is pleased to announce the company has been formally approved by the U.S. Patent Office for a continuation-in-part (CIP). A continuation-in-part (CIP) patent is a new application that repeats a substantial portion of an earlier “parent” application while adding brand new subject matter or improvements. The U.S. Patent Office has issued a patent number and will issue the patent on August 11, 2026. The CIP patent adds additional protection for nicotine, vitamins, and caffeine utilizing our micelle delivery technology. This new patent allows CTT Pharma the ability to use our technology to make dissolvable strips, gum, pouches, lozenges, and dissolving tablets. CTT will continue to spend time strengthening our patent portfolio as the company believes patents are an important aspect of the business.
About CTT Pharmaceutical Holdings, Inc.
CTT Pharmaceutical Holdings, Inc. is a pharmaceutical technology company specializing in oral drug delivery systems designed to provide rapid onset, enhanced patient convenience, and efficient absorption. The Company’s patented micelle based thin film platform is intended to offer a novel alternative to traditional dosage forms across pharmaceutical, therapeutic, and nutraceutical markets. CTT is focused on integrating scientific validation, scalable manufacturing, and regulatory preparedness to support long-term growth and product innovation.
Forward-Looking Statements
Forward-looking statements include statements regarding the Company’s plans, objectives, expectations, and intentions, including potential future business operations. Words such as anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, should, will, would and similar expressions identify forward-looking statements. These statements are based on management’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Important factors that could cause such differences include, but are not limited to: the timing and outcome of a potential partnership. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statements.
CTT Pharmaceutical Holdings, Inc.
813-606-0060